VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an equity research report by Maxim Group LLC. The piece discusses VistaGen’s strongest positioning yet, based on its pharmaceutical pipeline coupled with financing and a rising mental health pace. The report reads, “On 12/18, VistaGen announced pricing of an equity financing, raising gross proceeds of $100M (~$93M net) and bringing the company’s cash balance to ~$103M. Importantly, the financing included participation of some leading institutional health care investors, which in our view is further validation of VistaGen’s mental health-focused pipeline (NMDA modulation, nasal-active pherines (PH94B, PH10)) and management’s ability to execute. We are also now factoring in PH10 into our model and the increased cash balance, which raises our PT to $5, from $3.”
To view the report, visit https://ibn.fm/zbWAX
About VistaGen Therapeutics Inc.
VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.